THIS ARTICLE/PRESS RELEASE IS PAID FOR AND PRESENTED BY NTNU Norwegian University of Science and Technology - read more
Mouse study: Chemotherapy works better with nanotechnology
Nanotechnology may provide more effective treatment for patients with peritoneal cancer.
New research could be good news for people who develop peritoneal cancer in the future. Researchers have found that nanotechnology can increase chemotherapy’s effectiveness.
“This patient group needs more effective treatment methods,” Astrid Hyldbakk says.
She recently completed her doctorate at NTNU’s Department of Physics. She is now employed as a researcher for SINTEF Industry in Biotechnology and Nanomedicine.
Cancer in the stomach and intestinal region often spreads to the peritoneal cavity. Peritoneal cancer is difficult to detect, and therefore the cancer often develops long before treatment begins. Unfortunately, the treatment methods often work poorly.
“Late diagnoses and ineffective treatment mean that patients with peritoneal cancer do not have a good prognosis,” Hyldbakk says.
Chemotherapy drugs do not stay in the abdominal cavity for long enough
Surgery is the most common treatment for peritoneal cancer today, along with chemotherapy to kill any cancer cells that remain after surgery.
“But the chemotherapy drugs don’t stay in the abdominal cavity for long enough to work properly,” Hyldbakk says.
In addition, the chemo drugs can spread to healthy parts of the body, where they cause damage and can result in serious side effects. But Hyldbakk’s research provides hope for better treatment.
Chemotherapy works longer
“Encapsulating the medicine in tiny nanoparticles enables us to keep the medicine in the cavity longer. We can also specially design these nanoparticles so that they deliver the drugs primarily to the cancer cells rather than to healthy cells,” Hyldbakk says.
Hyldbakk studied this method as part of her doctoral research. She worked with research groups at NTNU, SINTEF, and the Norwegian Radium Hospital.
“We encapsulated the cytotoxic agent in nanoparticles. These are approximately 100 nanometres in diameter, or one ten-thousandth of a millimetre. We injected these into the peritoneum of mice and rats,” she says.
In other words, this treatment is not quite ready for use by humans yet. But Hyldbakk’s results are promising.
Binds to tumours and releases medicine
“The drug particles remain in the peritoneal cavity longer and bind specifically to the tumours. There, they open and release the cytotoxic agent directly to the cancer cells. A larger amount of the medicine reaches these cancer cells instead of the healthy tissue, thereby increasing the efficacy of the drug and reducing the side effects,” Hyldbakk says.
The research groups believe that delivering chemotherapy using nanoparticles is a highly promising new strategy for treating people who develop peritoneal cancer. More research is needed, however.
“Now we have to thoroughly characterise and test this method to ensure that the treatment is both safe and effective. This is an important step before we can use the technology on humans,” Hyldbakk says.
Last year, researchers from SINTEF created the company NaDeNo. This company will lead future work in collaboration with SINTEF and the Norwegian Radium Hospital. The hope is that they will one day soon be able to make this technology available to patients as well.
Reference:
Hyldbakk et al. Intraperitoneal administration of cabazitaxel-loaded nanoparticles in peritoneal metastasis models, Nanomedicine: Nanotechnology, Biology and Medicine, vol. 48, 2023. DOI: 10.1016/j.nano.2023.102656
Read more content from NTNU:
-
Artificial nose can sniff out damaged fruit and spoiled meat
-
Want to be the best? It’s all in your mindset
-
Millions of Earth's species remain unknown to us. Can we still identify them?
-
AI expert: We should not have AI that exploits people's weaknesses
-
Afghanistan veterans are more prone to anger
-
Could a digital driving instructor offer the same quality as a human, but at a lower cost?
